Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer

NCT02570711 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02570711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02570711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Proof-of-Concept Study of Nab-Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Terminated
Start date
October 13, 2015
Completion date
April 30, 2016
Enrollment
3 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer